WO2016159653A3 - 크립토코커스 네오포만스의 독성을 조절하는 신규 유전자 및 이의 용도 - Google Patents

크립토코커스 네오포만스의 독성을 조절하는 신규 유전자 및 이의 용도 Download PDF

Info

Publication number
WO2016159653A3
WO2016159653A3 PCT/KR2016/003255 KR2016003255W WO2016159653A3 WO 2016159653 A3 WO2016159653 A3 WO 2016159653A3 KR 2016003255 W KR2016003255 W KR 2016003255W WO 2016159653 A3 WO2016159653 A3 WO 2016159653A3
Authority
WO
WIPO (PCT)
Prior art keywords
cryptococcus neoformans
novel gene
cryptococcal
gene regulating
present
Prior art date
Application number
PCT/KR2016/003255
Other languages
English (en)
French (fr)
Other versions
WO2016159653A2 (ko
Inventor
반용선
정광우
양동훈
Original Assignee
오리젠바이오틱스(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리젠바이오틱스(주) filed Critical 오리젠바이오틱스(주)
Priority to EP16773434.2A priority Critical patent/EP3279330A4/en
Priority to US15/563,345 priority patent/US20180305728A1/en
Priority to EP20177048.4A priority patent/EP3739058B1/en
Publication of WO2016159653A2 publication Critical patent/WO2016159653A2/ko
Publication of WO2016159653A3 publication Critical patent/WO2016159653A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

본 발명의 크립토코커스 네오포만스의 병독성을 조절하는 신규 유전자 및 이의 용도에 관한 것이다. 본발명에 다라항크립토코커스또는 항진균 약물 후보 물질이 효과적으로 스크리닝될 수 있다. 또한， 본 발명은시판중인 항크립토코커스 또는 항진균 약물과 병용 투여되어 시너지 효과를 가져 올 수 있는 약물 후보 물질을 스크리닝하는 방법에 관한것이다. 또한， 전자인자의 발현을 증가시키거나 감소시킴에 의해 항크립 토코커스 또는 항진균 효과를 갖는 약학 조성물을 제공한다.
PCT/KR2016/003255 2015-03-30 2016-03-30 크립토코커스 네오포만스의 독성을 조절하는 신규 유전자 및 이의 용도 WO2016159653A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP16773434.2A EP3279330A4 (en) 2015-03-30 2016-03-30 NEW GENE REGULATING VIRULENCE DECRYPTOCOCCUS NEOFORMANS
US15/563,345 US20180305728A1 (en) 2015-03-30 2016-03-30 Novel gene regulating virulence of cryptococcus neoformans, and use thereof
EP20177048.4A EP3739058B1 (en) 2015-03-30 2016-03-30 Novel gene regulating virulence of cryptococcus neoformans, and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020150044621 2015-03-30
KR10-2015-0044621 2015-03-30
KR1020150044617 2015-03-30
KR10-2015-0044617 2015-03-30

Publications (2)

Publication Number Publication Date
WO2016159653A2 WO2016159653A2 (ko) 2016-10-06
WO2016159653A3 true WO2016159653A3 (ko) 2016-12-01

Family

ID=57005019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003255 WO2016159653A2 (ko) 2015-03-30 2016-03-30 크립토코커스 네오포만스의 독성을 조절하는 신규 유전자 및 이의 용도

Country Status (6)

Country Link
US (1) US20180305728A1 (ko)
EP (2) EP3279330A4 (ko)
DK (1) DK3739058T3 (ko)
ES (1) ES2963511T3 (ko)
PL (1) PL3739058T3 (ko)
WO (1) WO2016159653A2 (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110124941A (ko) * 2010-05-12 2011-11-18 연세대학교 산학협력단 진균 감염의 치료를 위한 Ｔｃｏ1, Ｍｂｐ1, Ａｔｆ1 또는 Ｒａｓ1의 용도
KR101403862B1 (ko) * 2012-12-11 2014-06-11 중앙대학교 산학협력단 진균 감염 또는 뇌수막염 치료를 위한 ｕｐｒ 신호전달 유전자 ｉｒｅ1 및 ｈｘｌ1의 용도
KR20150008298A (ko) * 2013-07-12 2015-01-22 중앙대학교 산학협력단 크립토코쿠시스 네오포만스에 의한 진균 감염 치료를 위한 당전이효소 유전자 CnKTR3의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010079998A2 (ko) * 2009-01-09 2010-07-15 연세대학교 산학협력단 진균 감염의 치료를 위한 hog, ras 및 camp 신호전달경로 유전자의 용도
KR101079278B1 (ko) * 2009-01-09 2011-11-04 연세대학교 산학협력단 진균 감염의 치료를 위한 ｈｏｇ 신호전달경로 유전자의 용도
KR101311196B1 (ko) * 2010-12-23 2013-09-27 중앙대학교 산학협력단 진균 감염 또는 뇌수막염 치료를 위한 ｕｐｒ 신호전달 유전자 ｉｒｅ1 및 ｈｘｌ1의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110124941A (ko) * 2010-05-12 2011-11-18 연세대학교 산학협력단 진균 감염의 치료를 위한 Ｔｃｏ1, Ｍｂｐ1, Ａｔｆ1 또는 Ｒａｓ1의 용도
KR101403862B1 (ko) * 2012-12-11 2014-06-11 중앙대학교 산학협력단 진균 감염 또는 뇌수막염 치료를 위한 ｕｐｒ 신호전달 유전자 ｉｒｅ1 및 ｈｘｌ1의 용도
KR20150008298A (ko) * 2013-07-12 2015-01-22 중앙대학교 산학협력단 크립토코쿠시스 네오포만스에 의한 진균 감염 치료를 위한 당전이효소 유전자 CnKTR3의 용도

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLORIO ET AL.: "Genome-wide Expression Profiling of the Response to Short-term Exposure to Fluconazole in Cryptococcus Neoformans Serotype A", BMC MICROBIOLOGY, vol. 11, no. 97, 11 May 2011 (2011-05-11), pages 1 - 13, XP021099691 *
KIM ET AL.: "Network-assisted Genetic Dissection of Pathogenicity and Drug Resistance in the Opportunistic Human Pathogenic Fungus Cryptococcus Neoformans", SCIENTIFIC REPORT, vol. 5, no. 8767, 5 March 2015 (2015-03-05), pages 1 - 10, XP055332074 *

Also Published As

Publication number Publication date
ES2963511T3 (es) 2024-03-27
DK3739058T3 (da) 2023-10-30
EP3739058A3 (en) 2021-01-27
WO2016159653A2 (ko) 2016-10-06
EP3279330A4 (en) 2019-02-20
EP3739058B1 (en) 2023-07-26
EP3739058A2 (en) 2020-11-18
EP3279330A2 (en) 2018-02-07
PL3739058T3 (pl) 2024-02-26
US20180305728A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
EP4292594A3 (en) Inhibitors of ret
WO2016170348A8 (en) Sarna compositions and methods of use
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
EP3191546A4 (en) Emulsion polymers including one or more 1,1-disubstituted alkene compounds, emulsion methods, and polymer compositions
CN106536480A8 (zh) 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法
WO2015143046A3 (en) Methods and compositions for regulation of zinc finger protein expression
NZ727281A (en) Stereochemically enriched compositions for delivery of nucleic acids
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
WO2014180889A8 (en) Methods and compositions for the treatment of cancer
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2016073847A3 (en) Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
EP3412292B8 (en) Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
WO2012087004A3 (en) Use of upr signaling pathway genes ire1 and hxl1 for treatment of fungal infection and meningitis
EP3560950A4 (en) NOVEL MUTANT OF ALFA-CONOTOXIN-PEPTIDE-TXID, PHARMACEUTICAL COMPOSITION AND USE OF IT
EP3122872A4 (en) Compositions and methods for treating type 1 and type 2 diabetes and related disorders
WO2018226992A8 (en) Tau aggregation inhibitors
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
EP3190129A4 (en) Centrally-acting peptide derivative, and pharmaceutical composition
EP3476401A4 (en) CELL DEATH INDUCER, CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A DISEASE ASSOCIATED WITH AN ABNORMAL CELL PROLIFERATION
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2015001541A3 (en) Pharmaceutical film composition
EP3474877A4 (en) MENTSH ANALOGUE AS THERAPEUTICS FOR DIABETES, ADIPOSITAS AND ASSOCIATED DISEASES AND COMPLICATIONS THEREOF
EP3320879A4 (en) COMPOSITION FOR IMPROVING PHOTOABTASPING AND METHOD FOR IMPROVING THE PHOTOACEPTING OF A PRODUCT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16773434

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15563345

Country of ref document: US